Article
The association between tumor mutational burden and prognosis is dependent on treatment context.
Nature genetics - 1 Jan 2021
Valero Cristina, Lee Mark, Hoen Douglas, Wang Jingming, Nadeem Zaineb, Patel Neal, Postow Michael A, Shoushtari Alexander N, Plitas George, Balachandran Vinod P, Smith J Joshua, Crago Aimee M, Long Roche Kara C, Kelly Daniel W, Samstein Robert M, Rana Satshil, Ganly Ian, Wong Richard J, Hakimi A Ari, Berger Michael F, Zehir Ahmet, Solit David B, Ladanyi Marc, Riaz Nadeem, Chan Timothy A, Seshan Venkatraman E, Morris Luc G T
Abstract excerpt
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 20% ICI-treated) with 17 cancer types before/without ICI treatment or after ICI treatment. In non-ICI-treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.